Comparison of the Major Clinical Outcomes for the Use of Endeavor® and Resolute Integrity® Zotarolimus-Eluting Stents During a Three-Year Follow-up
References
- Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2005; 1: 157–64.
- Di Santo P, Simard T, Ramirez FD, et al. Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute Integrity zotarolimus-eluting stents. Clin Invest Med. 2015; 38: E296–304. DOI: 10.25011/cim.v38i5.25686
- Hezi-Yamit A, Sullivan C, Wong J, et al. Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A. 2009; 90: 133–41. DOI: 10.1002/jbm.a.32057
- Udipi K, Chen M, Cheng P, et al. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A. 2008; 85: 1064–71. DOI: 10.1002/jbm.a.31664
- Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011; 57: 1778–83. DOI: 10.1016/j.jacc.2011.03.005
- Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006; 48: 2440–7. DOI: 10.1016/j.jacc.2006.08.035
- Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010; 55: 543–54. DOI: 10.1016/j.jacc.2009.08.067
- Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol. 2010; 56: 1187–95. DOI: 10.1016/j.jacc.2010.03.086
- Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet. 2010; 375: 1090–9. DOI: 10.1016/S0140-6736(10)60208-5
- Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J. 2000; 21: 1502–13. DOI: 10.1053/euhj.2000.2305
- Kim YH, Her AY, Jeong MH, et al. Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. Catheter Cardiovasc Interv. 2019; 93: 1264–75. DOI: 10.1002/ccd.27985
- Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95:
e2651 . DOI: 10.1097/MD.0000000000002651 - Kim YH, Her AY, Choi BG, et al. Routine angiographic follow-up versus clinical follow-up in patients with diabetes following percutaneous coronary intervention with drug-eluting stents in Korean population. Diabetes Res Clin Pract. 2018; 138: 138–48. DOI: 10.1016/j.diabres.2018.02.007
- Colmenarez H, Fernández C, Escaned J. Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents. EuroIntervention. 2014; 10: 942–52. DOI: 10.4244/EIJV10I8A161
- Turco MA. The Integrity bare-metal stent made by continuous sinusoid technology. Expert Rev Med Devices. 2011; 8: 303–6. DOI: 10.1586/erd.11.2
- Belardi JA, Albertal M. Integrity® coronary stent: a very limber bare-metal stent. Catheter Cardiovasc Interv. 2011; 78: 909. DOI: 10.1002/ccd.23414
- Tada T, Byrne RA, Cassese S, et al. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. Am Heart J. 2013; 165: 80–6. DOI: 10.1016/j.ahj.2012.10.019
- Iqbal MB, Nadra IJ, Din JN, et al. Prognostic significance of polymer coatings in zotarolimus-eluting stents. Am J Cardiol. 2016; 117: 735–42. DOI: 10.1016/j.amjcard.2015.11.056
- Cassese S, Ndrepepa G, King LA, Tada T, Fusaro M, Kastrati A. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison. Heart. 2012; 98: 1632–40. DOI: 10.1136/heartjnl-2012-302519
- Qian F, Zhong Y, Hannan EL. Long-term comparative effectiveness of Endeavor zotarolimus-eluting and everolimus-eluting stents in New York. Int J Cardiol. 2017; 241: 437–43. DOI: 10.1016/j.ijcard.2017.03.095
- Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005; 46: 253–60. DOI: 10.1016/j.jacc.2005.03.069
- van der Heijden LC, Kok MM, Löwik MM, et al. Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial. EuroIntervention. 2017; 12: 2128–31. DOI: 10.4244/EIJ-D-16-00571
- Kirtane AJ, Leon MB, Ball MW, et al. The “final” 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013; 6: 325–33. DOI: 10.1016/j.jcin.2012.12.123
DOI: https://doi.org/10.5334/gh.374 | Journal eISSN: 2211-8179
Language: English
Submitted on: Dec 20, 2019
Accepted on: Dec 20, 2019
Published on: Feb 6, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Yong Hoon Kim, Ae-Young Her, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.